title: Can monoamine-based therapies be improved?
authors.affiliation: Lilly Research Laboratories, Lilly Corporate Center, Drop Code 2066, Indianapolis, IN 46285, USA. madmd@lilly.com
authors.forename: Mark A
authors.initials: MA
authors.lastname: Demitrack
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D015306:Biogenic Monoamines / Q000037:antagonists & inhibitors / Q000378:metabolism*; D003511:Cyclohexanols / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D000068736:Duloxetine Hydrochloride; D006801:Humans; D017982:Receptors, Biogenic Amine / Q000187:drug effects / Q000378:metabolism; D013876:Thiophenes / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
chemical_list: D000319:Adrenergic beta-Antagonists; D000928:Antidepressive Agents; D015306:Biogenic Monoamines; D003511:Cyclohexanols; D017982:Receptors, Biogenic Amine; D013876:Thiophenes; D000069470:Venlafaxine Hydrochloride; D000068736:Duloxetine Hydrochloride